IMC-T119C

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameIMC-T119C

Drug Alias NameIMC-T-119-C

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulantsMelanoma antigen preferentially expressed in tumors modulators +[4]

TargetsMelanoma antigen preferentially expressed in tumorsT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaN/A

Originator CompaniesImmunocore Holdings PLC

China Registration ClassN/A

Develop Information

Active CompaniesImmunocore Holdings PLC

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A